Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

iPS Cell Differentiation01:22

iPS Cell Differentiation

2.8K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.8K
EPS and iPS Cells in Disease Research01:21

EPS and iPS Cells in Disease Research

2.9K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
2.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ESRP1-regulated DNMT3B isoform switching determines the malignant potential of pancreatic cancer.

Oncogene·2026
Same author

Association of Hemodynamic Disease Severity and Distribution With Risk of Future Acute Coronary Syndrome.

JACC. Cardiovascular imaging·2026
Same author

<i>In silico</i> cardiac safety assessment using a multi-biomarker approach based on an electrophysiological model of hiPSC-derived cardiomyocytes.

Toxicological research·2026
Same author

Acute coronary syndrome risk in coronary side branch versus main vessel lesions: Lumen, plaque, and hemodynamic insights from coronary CT angiography.

Journal of cardiovascular computed tomography·2026
Same author

Improving biomarker robustness for in silico cardiac safety assessment through an excitation-contraction coupling model.

Toxicology and applied pharmacology·2026
Same author

Mapping the Cell-Cell Interactions in Cardiovascular Diseases: A Single-Cell Atlas Perspective.

Korean circulation journal·2026

Related Experiment Video

Updated: Sep 14, 2025

Technical Applications of Microelectrode Array and Patch Clamp Recordings on Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes
10:30

Technical Applications of Microelectrode Array and Patch Clamp Recordings on Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes

Published on: August 4, 2022

3.0K

A machine learning platform for genotype-specific cardiotoxicity risk prediction using patient-derived iPSC-CMs.

Yun-Gwi Park1, Na Kyeong Park2, Youngsun Lee3

  • 1Department of Animal Science and Technology, College of Biotechnology and Natural Resources, Chung-Ang University, Anseong, 17546, Republic of Korea.

Journal of Advanced Research
|July 24, 2025
PubMed
Summary

Machine learning models using patient-derived cardiomyocytes predict drug-induced Torsades de Pointes risk. This platform enhances drug safety and precision medicine for inherited cardiac conditions.

Keywords:
Disease-specific predictionDrug-induced cardiotoxicityInduced pluripotent stem cell-derived cardiomyocytesInherited arrhythmiaMachine learning

More Related Videos

High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers
14:03

High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers

Published on: March 24, 2023

2.0K
Generation and Expansion of Human Cardiomyocytes from Patient Peripheral Blood Mononuclear Cells
05:38

Generation and Expansion of Human Cardiomyocytes from Patient Peripheral Blood Mononuclear Cells

Published on: February 12, 2021

4.3K

Related Experiment Videos

Last Updated: Sep 14, 2025

Technical Applications of Microelectrode Array and Patch Clamp Recordings on Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes
10:30

Technical Applications of Microelectrode Array and Patch Clamp Recordings on Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes

Published on: August 4, 2022

3.0K
High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers
14:03

High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers

Published on: March 24, 2023

2.0K
Generation and Expansion of Human Cardiomyocytes from Patient Peripheral Blood Mononuclear Cells
05:38

Generation and Expansion of Human Cardiomyocytes from Patient Peripheral Blood Mononuclear Cells

Published on: February 12, 2021

4.3K

Area of Science:

  • Cardiovascular Pharmacology
  • Stem Cell Biology
  • Computational Biology

Background:

  • Drug-induced Torsades de Pointes (TdP) necessitates market withdrawals, particularly for individuals with inherited cardiac channelopathies.
  • Patient-specific induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) offer a model for studying electrophysiological vulnerability.

Purpose of the Study:

  • To develop a machine learning (ML) platform for disease-specific cardiotoxicity assessment.
  • To integrate iPSC-CMs with high-throughput microelectrode array (MEA) recordings for drug screening.

Main Methods:

  • Generated and characterized iPSC-CMs from Long QT Syndrome (LQTS) and Brugada Syndrome (BrS) patients.
  • Exposed iPSC-CMs to 28 compounds, measuring electrophysiological responses via MEA.
  • Trained and validated ML models (ANN, random forest, XGBoost) using cross-validation.

Main Results:

  • An Artificial Neural Network (ANN) model using LQTS iPSC-CMs achieved high accuracy (AUC=0.94) in predicting TdP risk.
  • Identified distinct drug sensitivities: BrS cells to calcium blockers, LQTS cells to potassium inhibitors.
  • Reclassified ambiguous compounds based on disease-specific profiles, validating genotype-specific risk assessment.

Conclusions:

  • A scalable, individualized cardiotoxicity screening platform using patient-derived iPSC-CMs was developed.
  • The platform improves drug safety prediction and regulatory evaluation.
  • This approach advances precision medicine for arrhythmia risk assessment.